<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000074.pub2" GROUP_ID="NEONATAL" ID="601699081816433130" MERGED_FROM="" MODIFIED="2013-02-25 19:56:26 +0000" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Short title (no longer in use): Doxapram treatment for apnea&lt;/p&gt;&lt;p&gt;CL 4/04 (substantive update)&lt;/p&gt;&lt;p&gt;sent to Loni March 28/07&lt;/p&gt;&lt;p&gt;CL 3/07 minor update&lt;/p&gt;&lt;p&gt;sent to Loni for NICHD formatting July 11&lt;/p&gt;" NOTES_MODIFIED="2012-04-18 13:56:16 -0400" NOTES_MODIFIED_BY="Diane Haughton" REVIEW_NO="011" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.3">
<COVER_SHEET MODIFIED="2013-02-25 19:56:26 +0000" MODIFIED_BY="Diane Haughton">
<TITLE>Doxapram treatment for apnea in preterm infants</TITLE>
<CONTACT MODIFIED="2013-02-25 19:56:26 +0000" MODIFIED_BY="Diane Haughton"><PERSON ID="5306" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Diane</FIRST_NAME><LAST_NAME>Haughton</LAST_NAME><POSITION>Managing Editor, Cochrane Neonatal Group</POSITION><EMAIL_1>haughton@mcmaster.ca</EMAIL_1><URL>http://cochrane.mcmaster.ca/neonatal/</URL><ADDRESS><DEPARTMENT>Department of Pediatrics and Clinical Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1280 Main Street West</ADDRESS_1><ADDRESS_2>CRL, Room B102</ADDRESS_2><CITY>Hamilton</CITY><ZIP>L8S 4K1</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 525 9140 ext: 22897</PHONE_1><FAX_1>+1 905 521 5007</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-02-25 19:56:26 +0000" MODIFIED_BY="Diane Haughton"><PERSON ID="4691" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Henderson-Smart</LAST_NAME><ADDRESS><DEPARTMENT>(Deceased) Central Clinical School</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Sydney</ORGANISATION><CITY>Sydney</CITY><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="18344" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Steer</LAST_NAME><SUFFIX>MB, BS, FRACP, FRCPC,FAAP</SUFFIX><POSITION>Professor and Chief Executive Officer</POSITION><EMAIL_1>Peter_Steer@health.qld.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine, Faculty of Health Sciences, University of Queensland</DEPARTMENT><ORGANISATION>Children's Health Services District, Queensland Health</ORGANISATION><CITY>Brisbane</CITY><ZIP>L8N 3Z5</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>0409 639682</PHONE_1><FAX_1>7 3895 3221</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-06-29 14:13:37 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 14/05/07&lt;/p&gt;&lt;p&gt;New studies sought but none found: 23/05/07&lt;/p&gt;&lt;p&gt;Reformatted: 20/08/99&lt;/p&gt;" NOTES_MODIFIED="2009-06-29 14:13:37 -0400" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="4" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2012-04-18 13:56:16 -0400" MODIFIED_BY="Diane Haughton">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-04-18 13:56:16 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>Contact person changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-04-18 13:55:59 -0400" MODIFIED_BY="Diane Haughton">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-04-18 13:55:59 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="12" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-12-07 12:14:08 -0500" MODIFIED_BY="Diane Haughton">
<DATE DAY="27" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>This review updates the review "Doxapram treatment for apnea in preterm infants", published in the Cochrane Database of Systematic Reviews, Issue 3, 2007 (<LINK REF="REF-Henderson_x002d_Smart-2007" TYPE="REFERENCE">Henderson-Smart 2007</LINK>).</P>
<P>Our updated search did not identify any additional trials for inclusion in this update.</P>
<P>Conclusions unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-06-04 14:34:55 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-03 11:07:44 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>This review updates the existing review 'Doxapram treatment for apnea in preterm infants' published in The Cochrane Library, Disk Issue 4, 2004 (<LINK REF="REF-Henderson_x002d_Smart-2004" TYPE="REFERENCE">Henderson-Smart 2004</LINK>).<BR/>
<BR/>No additional eligible trials have been identified in this update and the conclusions are unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="29" MONTH="7" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Pediatrics, McMaster Childrens Hospital, Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Neonatal Medicine, Royal Prince Alfred Hospital, Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-12 12:24:33 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-06-17 12:30:55 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-03 11:07:11 -0400" MODIFIED_BY="[Empty name]">Doxapram treatment for apnea in preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2009-06-17 12:30:55 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram stimulates breathing. However, there is not enough evidence to know if it is helpful in premature infants with apnea. Infant apnea is a pause in breathing of greater than 20 seconds. This can be harmful to the developing brain and cause dysfunction of the gastrointestinal tract or other organs. Drugs such as doxapram are thought to stimulate breathing and are given to reduce apnea. The review of one small trial found that apnea might be reduced in the first few days after treatment, but there were not enough infants studied to know if this was a significant effect. There is no evidence from this trial on longer term effects or less common adverse effects. More research is needed on the effectiveness, potential harm and long-term benefits or adverse effects of these drugs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-12 12:24:33 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>Recurrent apnea is common in preterm infants, particularly at very early gestational ages. Apnea can lead to hypoxemia and bradycardia, which may be severe enough to require resuscitation including use of positive pressure ventilation. Doxapram has been used to stimulate breathing and thereby prevent apnea and its consequences.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-06-17 12:29:48 -0400" MODIFIED_BY="[Empty name]">
<P>To evaluate the effect of doxapram treatment on apnea and the use of intermittent positive airways pressure (IPPV) in preterm infants with recurrent apnea.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the Oxford Database of Perinatal Trials, the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, Issue 2, 2009), MEDLINE from 1966 to April 2009, EMBASE from 1980 to April 2009, CINAHL from 1982 to April 2009. We used the text words 'doxapram', 'apnea or apnoea' and the MeSH term 'infant, premature'. Previous reviews including cross references, abstracts from conferences and symposia proceedings were also examined. Abstracts of the Society for Pediatric Research were searched from 1996 to 2008 inclusive.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>We included all trials utilising random or quasi-random patient allocation in which doxapram was used for the treatment of apnea in preterm infants.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>Each review author evaluated the papers for quality and inclusion criteria and extracted data independently. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-12 12:24:33 -0400" MODIFIED_BY="[Empty name]">
<P>We found only one trial, which randomized 11 infants to intravenous doxapram and 10 infants to placebo. There were fewer treatment failures after 48 hours in the group of preterm infants treated with doxapram (4/11) compared with the group treated with placebo (8/10). The wide confidence intervals made this result non-significant [summary relative risk 0.45 (0.20 to 1.05)]. Only one infant, who was from the placebo group, was given IPPV.</P>
<P>Of the seven responders by 48 hours in the group of 11 who received doxapram, five failed to respond between 48 hours and seven days after commencement of therapy. This gives a late failure rate of 9/11, similar to the short-term failure rate in the placebo group of 8/10. It is not possible to evaluate the late responses of all those in the placebo group since they crossed over to a treatment arm.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-06-17 12:30:38 -0400" MODIFIED_BY="[Empty name]">
<P>Although intravenous doxapram might reduce apnea within the first 48 hours of treatment, there are insufficient data to evaluate the precision of this result or to assess potential adverse effects. No long-term outcomes have been measured. Further studies are needed to determine the role of this treatment in clinical practice.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-06-17 12:32:29 -0400" MODIFIED_BY="[Empty name]">
<P>Infant apnea is defined as a pause in breathing of greater than 20 seconds or one of less than 20 seconds associated with bradycardia, pallor and/or cyanosis (<LINK REF="REF-AAP-2003" TYPE="REFERENCE">AAP 2003</LINK>). Recurrent episodes of apnea are common in preterm infants and the incidence and severity increases at lower gestational ages. Although apnea can occur spontaneously and be attributed to prematurity alone, apnea can also be provoked or made more severe if there is some additional insult such as infection, hypoxemia or intracranial pathology.</P>
<P>If prolonged, apnea can lead to hypoxemia and reflex bradycardia that may require active resuscitative efforts to reverse. There are clinical concerns that these episodes might be harmful to the developing brain or cause dysfunction of the gastrointestinal tract or other organs, although there are no data to support this. Frequent episodes may be accompanied by respiratory failure of sufficient severity to lead to intubation and the use of intermittent positive pressure ventilation (IPPV).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-06-17 12:33:37 -0400" MODIFIED_BY="[Empty name]">
<P>Methylxanthines have been used in clinical practice to stimulate breathing efforts and reduce apnea since the 1970's. Doxapram also appears to stimulate breathing and may be an alternative treatment. </P>
</INTERVENTION>
<THEORY MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram appears to act both on the peripheral chemoreceptors and central nervous system to augment breathing efforts (reviewed by <LINK REF="REF-Barrington-1986" TYPE="REFERENCE">Barrington 1986</LINK>; Blanchard 1992).</P>
<P>Short-term side effects such as hypertension, excessive central nervous system stimulation, gastrointestinal disturbances (<LINK REF="REF-Tay_x002d_Uyboco-1991" TYPE="REFERENCE">Tay-Uyboco 1991</LINK>) and heart block (<LINK REF="REF-De-Villiers-1998" TYPE="REFERENCE">De Villiers 1998</LINK>) have been reported (<LINK REF="REF-Blanchard-1992" TYPE="REFERENCE">Blanchard 1992</LINK>). One observational study has suggested an association between the total dose and duration of doxapram treatment and isolated mental developmental delay in infants weighing less than 1250 grams at birth (<LINK REF="REF-Sreenan-2001" TYPE="REFERENCE">Sreenan 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-06-29 14:21:45 -0400" MODIFIED_BY="[Empty name]">
<P>For general reviews of apnea in preterm infants and its treatment see <LINK REF="REF-Samuels-1992" TYPE="REFERENCE">Samuels 1992</LINK> and <LINK REF="REF-Henderson_x002d_Smart-1995" TYPE="REFERENCE">Henderson-Smart 1995</LINK>. Other reviews compare doxapram and methylxanthines for apnea (<LINK REF="REF-Henderson_x002d_Smart-04c" TYPE="REFERENCE">Henderson-Smart 04c</LINK>) and evaluate doxapram to assist extubation of preterm infants (<LINK REF="REF-Henderson_x002d_Smart-04b" TYPE="REFERENCE">Henderson-Smart 04b</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effect of doxapram treatment on apnea and the use of IPPV in preterm infants with recurrent apnea.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All trials utilising random or quasi-random patient allocation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Preterm infants with recurrent apnea. There must have been an effort to exclude specific causes of apnea.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Doxapram used for the treatment of apnea.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>Measures of the severity of apnea as well as the response to treatment must have been consistent with an evaluation of 'clinical apnea' (<LINK REF="REF-AAP-2003" TYPE="REFERENCE">AAP 2003</LINK>).</P>
<P>
<B>Primary</B>
</P>
<OL>
<LI>Failed treatment (continuing apnea, or use of IPPV, or death during study)</LI>
<LI>Apnea frequency</LI>
<LI>Use of IPPV</LI>
<LI>Mortality</LI>
</OL>
<P>
<B>Secondary</B>
</P>
<OL>
<LI>Side effects including seizures, hypertension, gastrointestinal disturbances and heart block</LI>
<LI>Development (mental and motor evaluated with standard test and clinical examination) and growth in childhood</LI>
</OL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, Issue 2, 2009), the Oxford Database of Perinatal trials, MEDLINE from 1966 to April 2009, EMBASE from 1980 to April 2009, CINAHL from 1982 to April 2009. We used the text words 'doxapram', 'apnea or apnoea' and the MeSH term 'infant, premature'. We examined the titles and abstracts of all potentially eligible trials and checked the full text if there was doubt as to eligibility.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>We also examined previous reviews including cross references, abstracts from conferences and symposia proceedings (American Society for Pediatric Research, 1996 to 2008 and the European Society for Pediatric Research, 1996 to 2008). Prof. Y. Ogawa also made an expert informant's search in the Japanese language in 1996. We examined the titles and abstracts of all potentially eligible trials and checked the full text if there was doubt as to eligibility.</P>
<P>We searched clinical trials registries for ongoing or recently completed trials (clinicaltrials.gov; controlled-trials.com; and who.int/ictrp).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group.</P>
<STUDY_SELECTION MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>We included all randomized and quasi-randomized controlled trials fulfilling the selection criteria described. We reviewed the results of the search and separately selected the studies for inclusion. We resolved any disagreement by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-06-17 12:41:05 -0400" MODIFIED_BY="[Empty name]">
<P>Each review author extracted the data separately. Data were then compared and differences resolved.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>We assessed the methodological quality of the one included trial for the method of randomization, blinding of intervention, blinding of outcome, and completeness of follow-up. The methodological quality of the trial was reviewed independently by the second review author blinded to trial authors and institution(s). We have requested additional information from the authors of the study to clarify methodology.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-06-17 12:41:18 -0400" MODIFIED_BY="[Empty name]">
<P>Treatment effect was expressed as relative risk (RR), risk difference (RD) and number needed to treat (NNT) derived from 1/RD. The precision of the estimate of treatment effect was expressed as the 95% confidence interval.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-06-29 14:13:12 -0400" MODIFIED_BY="[Empty name]">
<P>If a meta-analysis was performed, we planned to examine heterogeneity between trials by inspecting the forest plots and quantifying the impact of heterogeneity using the I-squared statistic. </P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>If meta-analysis was judged to be appropriate, the analysis would be done using Review Manager software (RevMan 5), supplied by The Cochrane Collaboration. For estimates of typical relative risk and risk difference, we planned to use the Mantel-Haenszel method. For measured quantities, we planned to use the inverse variance method. All meta-analyses were to be done using the fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-06-29 14:13:16 -0400" MODIFIED_BY="[Empty name]">
<P>If we detected statistical heterogeneity, we planned to explore the possible causes (for example, differences in study quality, participants, intervention regimens, or outcome assessments) using subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>We found only one small study comparing short term (48 hours) response to intravenous doxapram with placebo (<LINK REF="STD-Peliowski-1990" TYPE="STUDY">Peliowski 1990</LINK>). This trial had three arms: Aminophylline, Doxapram and control. For the purpose of this review, we present data from the latter two arms. Details are given in the Characteristics of included studies table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>Details are given in the Characteristics of included studies table. Co-interventions, such as continuous positive airways pressure, were used in an unknown number of cases and controls. Three infants were withdrawn after trial entry; one because parents withdrew consent; one because of possible infection; and a third because of possible seizures. The groups to which these infants were assigned is not given and none of their data were analysed. Since seizures are known to complicate doxapram therapy, this needs clarification from the study author.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-07-22 16:37:46 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>DOXAPRAM TREATMENT VS. PLACEBO (Comparison 1):<BR/>
</B>
<BR/>
<B>Failed treatment in first 48 hours (Outcome 1.1):<BR/>
</B>There were fewer treatment failures after 48 hours (continuing apnea and/or use of mechanical ventilation) in the group of preterm infants treated with doxapram (4/11) compared with the group treated with placebo (8/10). The wide confidence interval made this result non-significant (summary RR 0.45 (0.20 to 1.05)). Only one infant, who was from the placebo group, was given IPPV.</P>
<P>Of the seven responders by 48 hours in the group of 11 who received doxapram, five failed to respond between 48 hours and seven days after commencement of therapy. This gives a late failure rate of 9/11, similar to the short term failure rate in the placebo group of 8/10. It is not possible to evaluate the 48 hour to seven day responses of all those in the placebo group since they crossed over to a treatment arm. Two in the placebo group were considered longer term responders without treatment.<BR/>
<BR/>No adverse effects or outcomes beyond seven days from the commencement of treatment were reported.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-06-04 14:49:28 -0400" MODIFIED_BY="[Empty name]">
<P>The results of this small trial suggests that intravenous doxapram might reduce apnea of prematurity in the short term. Any possible effects of treatment were not sustained between 48 hours and seven days after commencement of doxapram treatment. The efficacy of doxapram for the short term control of apnea in preterm infants appears to be similar to that of methylxanthines (<LINK REF="REF-Henderson_x002d_Smart-04a" TYPE="REFERENCE">Henderson-Smart 04a</LINK>).</P>
<P>Caution is warranted as the sample size is inadequate to evaluate doxapram for either benefit or harm. There were no side effects observed in the infants included in the study. One excluded infant had suspected seizures although the original group assignment was not given. Heart block has been reported by others (<LINK REF="REF-De-Villiers-1998" TYPE="REFERENCE">De Villiers 1998</LINK>), but was not observed in the included study.</P>
<P>One observational study has suggested an association between the total dose and duration of doxapram treatment and isolated mental developmental delay in infants weighing less than 1250 grams at birth (<LINK REF="REF-Sreenan-2001" TYPE="REFERENCE">Sreenan 2001</LINK>). As discussed by the authors, they could not control for the severity of apnea, which has also been associated with poor neurodevelopmental outcome (<LINK REF="REF-Cheung-1999" TYPE="REFERENCE">Cheung 1999</LINK>). Another suggested source of toxicity is benzyl alcohol used in the intravenous preparation of doxapram in the USA. It has been pointed out that the <LINK REF="REF-Sreenan-2001" TYPE="REFERENCE">Sreenan 2001</LINK> observations were made in Canada where doxapram does not contain benzyl alcohol (<LINK REF="REF-Finer-2002" TYPE="REFERENCE">Finer 2002</LINK>).</P>
<P>An important limitation to the use of doxapram is that it is usually administered intravenously. Although observational studies suggest that it can be given orally, only about 50% is absorbed and gastrointestinal side effects have been reported (<LINK REF="REF-Bairam-1991" TYPE="REFERENCE">Bairam 1991</LINK>; <LINK REF="REF-Tay_x002d_Uyboco-1991" TYPE="REFERENCE">Tay-Uyboco 1991</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-06-04 14:49:33 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-06-04 14:49:33 -0400" MODIFIED_BY="[Empty name]">
<P>Although intravenous doxapram might reduce apnea within the first 48 hours of treatment, there are insufficient data to evaluate the precision of this result or to assess known potential adverse effects. No long term outcomes have been measured. Further studies are needed to determine the role of this treatment in clinical practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a need for studies of a larger number of infants stratified by gestation to clarify which infants are likely to benefit from this treatment. It would be valuable to include important clinical outcomes such as use of IPPV, side effects and subsequent growth and development in future studies.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-12 12:21:52 -0400" MODIFIED_BY="[Empty name]">
<P>The Cochrane Neonatal Review Group has been funded in part with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN267200603418C.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-06-04 14:43:43 -0400" MODIFIED_BY="[Empty name]">
<P>Both review authors developed the protocol, evaluated trials and extracted data. <BR/>Henderson-Smart wrote the review and entered data into RevMan. <BR/>Henderson-Smart has been responsible for searching for trials and updating the review with approval of Steer.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-07-22 16:38:43 -0400" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Peliowski-1990" NAME="Peliowski 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Peliowski A, Finer NN. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. J Pediatr 1990;116:648-653.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peliowski A, Finer NN</AU>
<TI>A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>116</VL>
<PG>648-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Poets-1999" NAME="Poets 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poets CF, Darraj S, Bohnhorst B</AU>
<TI>Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants</TI>
<SO>Biology of the Neonate</SO>
<YR>1999</YR>
<VL>76</VL>
<PG>207-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-07-22 16:38:43 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-07-22 16:38:43 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AAP-2003" NAME="AAP 2003" NOTES="&lt;p&gt;American Academy of Pediatrics, Policy statement. Apnea, Sudden Infant Death Syndrome, and home monitoring. Pediatrics 2003; 111:914-917.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Pediatrics</AU>
<TI>Policy statement. Apnea, sudden infant death syndrome, and home monitoring</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>111</VL>
<PG>914-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bairam-1991" NAME="Bairam 1991" NOTES="&lt;p&gt;Bairam A, Akramoff-Gersham L, Beharry K, et al. Gastrointestinal absorption of doxapram in neonates. Am J Perinatol 1991; 8: 110-113&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bairam A, Akramoff-Gershan L, Beharry K, Laudignon N, Papageorgiou A, Aranda JV</AU>
<TI>Gastrointestinal absorption of doxapram in neonates</TI>
<SO>American Journal of Perinatology</SO>
<YR>1991</YR>
<VL>8</VL>
<PG>110-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barrington-1986" NAME="Barrington 1986" NOTES="&lt;p&gt;Barrington KJ, Finer NN, Peters KL, Barton J. Physiological effects of doxapram in idiopathic apnea of prematurity. J Pediatr 1986; 108:125-129&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Barrington KJ, Finer NN, Peters KL, Barton J</AU>
<TI>Physiological effects of doxapram in idiopathic apnea of prematurity</TI>
<SO>Journal of Pediatrics</SO>
<YR>1986</YR>
<VL>108</VL>
<PG>125-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blanchard-1992" MODIFIED="2009-07-22 16:38:16 -0400" MODIFIED_BY="[Empty name]" NAME="Blanchard 1992" NOTES="&lt;p&gt;Blanchard PW and Aranda JV. Pharmacotherapy of respiratory control disorders. In: Beckerman RC, Brouillette RT, Hunt CE (eds), Respiratory Control Disorders in Infants and Children. Baltimore: Williams &amp;amp; Wilkins 1992 pp 352-370.&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:38:16 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="BOOK_SECTION">
<AU>Blanchard PW, Aranda JV</AU>
<TI>Pharmacotherapy of respiratory control disorders</TI>
<SO>Respiratory Control Disorders in Infants and Children</SO>
<YR>1992</YR>
<PG>352-70</PG>
<ED>Beckerman RC, Brouillette RT, Hunt CE</ED>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheung-1999" NAME="Cheung 1999" NOTES="&lt;p&gt;Cheung PY, Barrington KJ, Finer NN, Robertson CM. Early childhood neurodevelopment in very low birth weight infants with predischarge apnea. Pediatric Pulmonology. 1999; 27:14-20&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cheung PY, Barrington KJ, Finer NN, Robertson CM</AU>
<TI>Early childhood neurodevelopment in very low birth weight infants with predischarge apnea</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>27</VL>
<PG>14-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Villiers-1998" MODIFIED="2009-06-29 14:34:14 -0400" MODIFIED_BY="[Empty name]" NAME="De Villiers 1998" NOTES="&lt;p&gt;De Villiers GS, Walele A, Van der Merwe P-L, et al. Second-degree atrioventricular heart block after doxapram administration. J Pediatr 1998; 133:149-150&lt;/p&gt;" NOTES_MODIFIED="2009-06-29 14:34:14 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>De Villiers GS, Walele A, Van der Merwe PL, Kalis NN</AU>
<TI>Second-degree atrioventricular heart block after doxapram administration</TI>
<SO>Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>133</VL>
<PG>149-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finer-2002" NAME="Finer 2002" NOTES="&lt;p&gt;Finer NN, Barrington KJ. Doxapram and neurodevelopmental outcome (Letter). Journal of Pediatrics. 2002, 141:296&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Finer NN, Barrington KJ</AU>
<TI>Doxapram and neurodevelopmental outcome (Letter)</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>141</VL>
<PG>296</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-04a" MODIFIED="2009-07-14 15:03:48 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 04a" NOTES="&lt;p&gt;Henderson-Smart DJ, Davis PG. Prophylactic methylxanthine for extubation in preterm infants &lt;br&gt;(Cochrane Review). In: The Cochrane Library, Issue 2, 1999. Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2009-07-14 15:03:48 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Steer PA</AU>
<TI>Methylxanthine treatment for apnea in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-14 15:03:48 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-14 15:03:48 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000140"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-04b" MODIFIED="2009-07-14 15:04:26 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 04b" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Davis PG</AU>
<TI>Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-14 15:04:26 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-14 15:04:26 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001966"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-04c" MODIFIED="2009-07-14 15:04:09 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 04c" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Steer PA</AU>
<TI>Doxapram versus methylxanthine for apnea in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-14 15:04:09 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-14 15:04:09 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000075"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-1995" NAME="Henderson-Smart 1995" NOTES="&lt;p&gt;Henderson-Smart DJ. Recurrent apnoea. In: Bailliere's Clinical Paediatrics. Vol 3 No. 1 Pulmonary Problems in the Perinatal Period and their Sequelae. Ed Yu VYH, Bailliere Tindall, London, 1995 pp203-222.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Henderson-Smart DJ</AU>
<TI>Recurrent apnoea</TI>
<SO>Bailliere's Clinical Paediatrics. Pulmonary Problems in the Perinatal Period and their Sequelae</SO>
<YR>1995</YR>
<VL>3, No. 1</VL>
<PG>203-22</PG>
<ED>Yu, VYH</ED>
<PB>Bailliere Tindall</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Samuels-1992" MODIFIED="2009-07-22 16:38:43 -0400" MODIFIED_BY="[Empty name]" NAME="Samuels 1992" NOTES="&lt;p&gt;Samuels MP, Southall DP. Recurrent apnea. In: Sinclair JC, Bracken MB (eds). Effective Care of the Newborn Infant, Oxford. Oxford University Press 1992, pp 385-397.&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 16:38:43 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="BOOK_SECTION">
<AU>Samuels MP, Southall DP</AU>
<TI>Recurrent apnea</TI>
<SO>Effective Care of the Newborn Infant</SO>
<YR>1992</YR>
<PG>385-97</PG>
<ED>Sinclair JC, Bracken MB</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sreenan-2001" MODIFIED="2009-06-04 14:42:38 -0400" MODIFIED_BY="[Empty name]" NAME="Sreenan 2001" NOTES="&lt;p&gt;Screenan C, Etches PC, Demianczuk N, Robertson CMT. Isolated mental developmental delay in low birth weight infants: assosciatio with prologed doxapram therapy for apnea. Journal of Pediatrics. 2001, 139:832-837&lt;/p&gt;" NOTES_MODIFIED="2009-06-04 14:42:38 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Sreenan C, Etches PC, Demianczuk N, Robertson CMT</AU>
<TI>Isolated mental developmental delay in low birth weight infants: association with prolonged doxapram therapy for apnea</TI>
<SO>Journal of Pediatrics</SO>
<YR>2001</YR>
<VL>139</VL>
<PG>832-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tay_x002d_Uyboco-1991" NAME="Tay-Uyboco 1991" NOTES="&lt;p&gt;Tay-Uyboco J, Kwiatkowski K, Cates DB, et al. Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. Biol Neonate 1991; 59:190-200&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tay-Uyboco J, Kwiatkowski K, Cates DB, Seifert B, Hasan SU, Rigatto H</AU>
<TI>Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity</TI>
<SO>Biology of the Neonate</SO>
<YR>1991</YR>
<VL>59</VL>
<PG>190-200</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-07-14 15:06:10 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Henderson_x002d_Smart-1997" MODIFIED="2009-06-29 14:31:32 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 1997" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Steer PA</AU>
<TI>Doxapram for apnea in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2009-06-04 14:40:31 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-04 14:40:31 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000074.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-1999" MODIFIED="2009-06-29 14:31:41 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 1999" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Steer PA</AU>
<TI>Doxapram for apnea in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2009-06-04 14:41:10 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-04 14:41:10 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000074.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-2001" MODIFIED="2009-06-29 14:31:48 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 2001" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Steer PA</AU>
<TI>Doxapram for apnea in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-06-04 14:41:18 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-04 14:41:18 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000074.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-2004" MODIFIED="2009-06-04 14:41:26 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 2004" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Steer PA</AU>
<TI>Doxapram treatment for apnea in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-06-04 14:41:26 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-04 14:41:26 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000074.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-2007" MODIFIED="2009-07-14 15:06:10 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 2007" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Steer PA</AU>
<TI>Doxapram treatment for apnea in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-07-14 15:06:10 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-14 15:06:10 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000074.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-22 16:37:47 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-07-22 16:37:47 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-07-22 16:37:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peliowski-1990">
<CHAR_METHODS MODIFIED="2009-07-22 16:37:47 -0400" MODIFIED_BY="[Empty name]">
<P>Concealed at randomization - yes (computer generated randomization code - placed in sealed envelopes); Blinding of intervention - yes;<BR/>Complete follow-up - Unclear (three withdrawals, groups not specified)<BR/>Blinding of outcome assessment - yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-29 14:30:22 -0400" MODIFIED_BY="[Empty name]">
<P>21 preterm infants (&lt; 35 weeks gestation) with apnea (apnea &gt; 20 sec with &gt; 25% fall in heart rate and 10% fall in oxygen saturation or 5 torr or more fall in transcutaneous oxygen tension; 0.33 or more events per hr, = 8 or more per day) ; other causes of apnea excluded; similar mean gestational age (30.7 vs 31.3 weeks), birth weight (1441 vs 1303 gm), postnatal age at study entry (4.8 vs 2.9 days) and baseline apnea rate (0.94 vs 0.70/hr).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-29 14:30:26 -0400" MODIFIED_BY="[Empty name]">
<P>Doxapram intravenously; 3 mg/kg load and 1.5 mg/kg/hr vs saline placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-29 14:30:30 -0400" MODIFIED_BY="[Empty name]">
<P>Apnea at 48 hours (failure of rate of events to fall below 0.33/hr or use of mechanical ventilation); use of IPPV.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Cross over design and simultaneous comparison with doxapram - not evaluated here.<BR/>Additional treatment with CPAP allowed - no information on who received this (author clarification requested).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Poets-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study is listed in databases as a randomized controlled trial. This is not stated in the methodology of the paper and author clarification has confirmed that it is not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-06-29 14:16:27 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-06-29 14:16:21 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 14:16:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peliowski-1990">
<DESCRIPTION>
<P>Concealed at randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-06-17 12:38:24 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-17 12:38:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peliowski-1990">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-06-17 12:43:01 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-06-17 12:43:01 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peliowski-1990">
<DESCRIPTION>
<P>Blinding of intervention and outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-06-29 14:16:27 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-29 14:16:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peliowski-1990">
<DESCRIPTION>
<P>Three infants (9.7%) withdrawn, groups not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-06-24 07:33:34 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-24 07:33:34 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peliowski-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-06-24 07:37:21 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-24 07:37:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peliowski-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Doxapram vs placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0538827390145467" CI_START="0.1960479687153146" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.022792291491360042" LOG_CI_START="-0.7076376531357724" LOG_EFFECT_SIZE="-0.3424226808222063" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.06611446917773801" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="1.8376467910109515">
<NAME>Failed treatment in first 48 hours</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0538827390145464" CI_START="0.1960479687153146" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.022792291491359952" LOG_CI_START="-0.7076376531357724" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="258" O_E="0.0" SE="0.4290581651605165" STUDY_ID="STD-Peliowski-1990" TOTAL_1="11" TOTAL_2="10" VAR="0.18409090909090906" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.743995250339148" CI_START="0.013844048529863517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.8289172557518838" LOG_CI_START="-1.858736886970008" LOG_EFFECT_SIZE="-0.5149098156090621" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.452656887989521" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="0.7509929777332595">
<NAME>Use of IPPV in first 48 hours</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.743995250339148" CI_START="0.013844048529863517" EFFECT_SIZE="0.3055555555555556" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8289172557518838" LOG_CI_START="-1.858736886970008" LOG_EFFECT_SIZE="-0.5149098156090621" ORDER="259" O_E="0.0" SE="1.5787413475374117" STUDY_ID="STD-Peliowski-1990" TOTAL_1="11" TOTAL_2="10" VAR="2.492424242424242" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>